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Introduction: Controversy exists regarding optimal treatment for ventilator-associated pneumonia (VAP) due to
methicillin-resistant Staphylococcus aureus (MRSA). The primary objective of this study was to compare clinical
success of linezolid versus vancomycin for the treatment of patients with MRSA VAP.
Methods: This was a multicenter, retrospective, observational study of patients with VAP (defined according to
Centers for Disease Control and Prevention criteria) due to MRSA who were treated with linezolid or vancomycin.
MRSA VAP was considered when MRSA was isolated from a tracheal aspirate or bronchoalveolar lavage. Clinical
success was evaluated by assessing improvement or resolution of signs and symptoms of VAP by day 14. After
matching on confounding factors, logistic regression models were used to determine if an association existed
between treatment arm and clinical success.
Results: A total of 188 patients were evaluated (101 treated with linezolid and 87 with vancomycin). The
mean ± standard deviation Acute Physiology and Chronic Health Evaluation (APACHE) II score was 21 ± 11
for linezolid- and 19 ± 9 for vancomycin-treated patients (P = 0.041). Clinical success occurred in 85% of
linezolid-treated patients compared with 69% of vancomycin-treated patients (P = 0.009). After adjusting for
confounding factors, linezolid-treated patients were 24% more likely to experience clinical success than
vancomycin-treated patients (P = 0.018).
Conclusions: This study adds to the evidence indicating that patients with MRSA VAP who are treated with
linezolid are more likely to respond favorably compared with patients treated with vancomycin.Introduction
Methicillin-resistant Staphylococcus aureus (MRSA) is
one of the primary multidrug-resistant pathogens caus-
ing healthcare-associated infections in the United States
[1]. Healthcare-associated respiratory infections caused
by MRSA, including healthcare-associated pneumonia
(HCAP), hospital-acquired pneumonia (HAP), and ventila-
tor-associated pneumonia (VAP), are important causes of* Correspondence: p0peyr01@louisville.edu; j.ramirez@louisville.edu
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unless otherwise stated.morbidity and mortality [2]. National guidelines for the
management of these patients were published by the
American Thoracic Society (ATS)/Infectious Diseases
Society of America (IDSA) in 2005 [2]. The guidelines
placed vancomycin and linezolid at similar levels of effi-
cacy and recommended either antibiotic as appropriate
therapy.
The results of the only prospective, randomized,
double-blind clinical trial exclusively enrolling patients
with MRSA healthcare-associated respiratory infections
that compared the clinical efficacy of vancomycin versusLtd. This is an Open Access article distributed under the terms of the Creative
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the national guidelines [3]. In this trial, linezolid-treated
patients had a higher clinical success rate compared with
vancomycin-treated patients. Although the sub-analysis
of patients with VAP in this study indicated a 55% clin-
ical success rate for linezolid and a 46% clinical success
rate for vancomycin, this difference was not statistically
significant [3]. In the field of critical care medicine, this
study did not completely resolve the controversy regard-
ing optimal therapy for patients with MRSAVAP.
The Improving Medicine through Pathway Assessment
of Critical Therapy in Hospital-Acquired Pneumonia
(IMPACT-HAP) study was created in 2006 by a group of
clinical investigators interested in healthcare-associated
respiratory infections [4,5]. Considering the persistent
controversy regarding the treatment of MRSA VAP, the
IMPACT-HAP group performed the current study with
the primary objective of comparing clinical success rates
for patients with MRSA VAP who were treated with
linezolid or vancomycin. As secondary study objectives,
mortality, safety, and resource utilization were compared
between the two groups.
Methods
Study design and study sites
IMPACT-HAP was a multicenter, retrospective, observa-
tional study of intensive care unit (ICU) patients with
MRSA VAP who were treated with linezolid or vanco-
mycin. The following five tertiary academic medical cen-
ters in the United States participated in the study: the
University of Louisville Medical Center (Louisville, KY,
USA), Henry Ford Health System (Detroit, MI, USA),
University of Miami/Jackson Memorial Hospital (Miami,
FL, USA), Summa Health System (Akron, OH, USA), and
Michigan State University (East Lansing, MI, USA). The
study was conducted from November 2008 through
October 2012. Patient data were collected on a case report
form, entered into a web-based database, and transferred
electronically to the University of Louisville Clinical and
Translational Research Support Center for data validation
and quality. The study was approved by the institutional
review board at each participating institution (University
of Louisville Human Subjects Protection Program Office;
Summa Health System Institutional Review Board; Michigan
State University Human Research Protection Program;
Henry Ford Health System Institutional Review Board;
University of Miami Human Subjects Research Office), all
of which waived the requirement for informed consent
since this was a retrospective observational study.
Study population and measurements
Inclusion criteria
Adult patients in participating ICUs meeting the study
definition of MRSA VAP were eligible for inclusion. VAPwas defined according to the Centers for Disease Control
and Prevention (CDC) National Healthcare Safety Network
surveillance definitions [6]. VAP was considered to be due
to MRSA when isolated from tracheal aspirates, bronchoal-
veolar lavage obtained by bronchoscopy, or blinded bron-
choalveolar lavage. Patients must have received more than
48 hours of either vancomycin or linezolid.
Exclusion criteria
Patients with a ‘comfort care’ or ‘do not resuscitate’ order
and patients who developed clinical failure during the
initial 48 hours of antibiotic therapy were excluded from
the study. In clinical practice, ICU physicians change anti-
biotics due to their own preferences without the evidence
of patients’ clinical deterioration. Patients were also exclu-
ded if there was a switch from vancomycin to linezolid or
vice versa after 48 hours in a patient without evidence of
clinical failure.
Study variables
At the time of clinical diagnosis of VAP (day 0), data on
patients’ demographic and baseline characteristics, severity
of illness including Acute Physiology and Chronic Health
Evaluation (APACHE) II score and Clinical Pulmonary In-
fection Score, diagnostic procedures, and treatment were
collected. While hospitalized, patients were followed until
discharge, death, or 28 days after VAP diagnosis, whichever
occurred first. Laboratory values were collected during
hospitalization. Identification of MRSA isolates and in vitro
susceptibility were performed at each participating center.
Vancomycin serum trough levels were collected through-
out the study period.
Study outcomes
Primary study outcome
Clinical Success: defined as improvement or resolution
of the signs and symptoms of VAP. This outcome was
evaluated at day 14 or hospital discharge, whichever oc-
curred first. To be considered a clinical success, patients
must have received at least five days of either vancomycin
or linezolid.
Secondary study outcomes
Mortality: defined as all-cause mortality within 14 days
after VAP diagnosis.
Thrombocytopenia: defined as a platelet count <150,000
cells/mm3 or a 50% decrease in platelet count if low at
baseline. Platelet count within 24 hours of VAP diagnosis
was defined as the baseline value.
Anemia: defined as hemoglobin ≤10 g/dL or a 2 g/dL
decrease if low at baseline. Hemoglobin level within
24 hours of VAP diagnosis was defined as the baseline
value.
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ine of 0.5 mg/dL or 50% above baseline, whichever was
greater, in ≥2 consecutive measurements. Serum creatin-
ine level within 24 hours of VAP diagnosis was defined as
the baseline value.
Resource utilization
For each study group, resource utilization was evaluated
by the following outcomes: 1) days on mechanical ventila-
tion, calculated as the number of days from VAP diagnosis
to extubation or to discharge if not extubated; 2) length of
stay (LOS) in the ICU, calculated as the number of days
from VAP diagnosis to discharge from the ICU; and 3)
LOS in the hospital, calculated as the number of days
from VAP diagnosis to discharge from the hospital.
Statistical analysis
Categorical variables were expressed as frequencies and
percentages and were compared between the treatment
groups using chi-squared or Fisher’s exact tests. Continu-
ous variables were expressed as medians and interquartile
ranges or means and standard deviations and were com-
pared between groups using the Mann-Whitney U test or
the Student’s t test. P values ≤0.05 were considered statis-
tically significant in all analyses unless otherwise specified.
Clinical success
In-depth methods for comparing clinical success between
the treatment groups are explained in Additional file 1.
Briefly, we used absolute standardized differences and
relative effect statistics to assess for covariate imbalances
between patients treated with vancomycin and linezolid
[7]. This allowed us to evaluate small imbalances in the
data that other traditional methods of confounding iden-
tification may have missed. To correct for imbalances (for
example, confounding effects), we used a multivariate
matching algorithm to match each patient treated with
linezolid to one patient treated with vancomycin who was
most similar with respect to all confounding variables ana-
lyzed [8]. This produced a matched dataset for which we
re-assessed the covariate imbalance again using the abso-
lute standardized difference and relative effect statistics.
Any variables that remained imbalanced between the
treatment groups were included as covariates in a final
logistic regression model.
We also performed sensitivity analyses using other
methods of covariate balance. A description of these
methods also can be found in Additional file 1. Since the
odds ratio (OR) generated from this logistic regression
model may be a poor descriptor of the actual risk when
the prevalence of the outcome is high (for example, high
rates of clinical success), the OR was adjusted to reflect
the relative risk of obtaining the outcome [9]. Using
results from these models, the adjusted number neededto treat was calculated according to published proce-
dures [10].
A propensity score containing all variables that were
unbalanced according to the unmatched absolute stan-
dardized difference calculation described previously was
created. The propensity score was included in a final
logistic regression model to adjust for confounding ef-
fects between the treatment and outcome. The predicted
probabilities of clinical success at day 14 were plotted in
a line graph against the APACHE II score for each treat-
ment group.
Safety
Kaplan-Meier survival curves were used to examine the
statistical differences between linezolid and vancomycin
treatment in the time to each of the safety outcomes
(thrombocytopenia, anemia, nephrotoxicity). The log-rank
test was used to assess statistical significance.
Resource utilization
Kaplan-Meier survival curves were created to evaluate
the bivariate relationships between treatment groups and
resource utilization (time on mechanical ventilation,
LOS in the ICU, and LOS in the hospital).
Statistical software
R software version 2.15.1 was used for all analyses including
the following packages: MatchIt [8], matching [11], non-
random [12], rgenoud [13], car [14], Zelig [15], Cairo [16],
survival [17], and Hmisc [18].
Results
Patient characteristics
A total of 188 patients diagnosed with MRSA VAP were
included in this analysis, of whom 101 were treated with
linezolid and 87 with vancomycin. A comparison of
baseline characteristics between the treatment groups is
depicted in Table 1. Linezolid-treated patients were sig-
nificantly more likely to be hospitalized for ≥5 days be-
fore VAP diagnosis and to have bronchiectasis, end-stage
liver disease, or severe sepsis. Linezolid-treated patients
also had significantly higher APACHE II scores and
significantly lower hemoglobin levels at diagnosis. The
rate of Clostridium difficile infection in each arm was as
follows: linezolid arm, 12 (12%); vancomycin arm 11 (13%);
P = 0.873. Additional results associated with methods
described in Additional file 1 can be found in Additional
files 2, 3, and 4.
MRSA minimum inhibitory concentrations (MICs) to
vancomycin also are depicted in Table 1. The mean ±
standard deviation (SD) vancomycin trough level at day 3
was 13 ± 8 μg/mL for vancomycin-treated patients. The
mean ± SD duration of treatment was 11 ± 4 days for
Table 1 Baseline characteristics of adult intensive care unit patients with ventilator-associated pneumonia due to
methicillin-resistant Staphylococcus aureus treated with linezolid or vancomycin
Characteristic Linezolid (n = 101) Vancomycin (n = 87) P value
Male, n (%) 63 (62.4) 49 (56.3) 0.457
Hospitalization ≥5 days before therapy for VAP, n (%) 74 (73.3) 50 (57.5) 0.030
Bronchiectasis, n (%) 8 (7.9) 1 (1.1) 0.039
Colonization with MDRO, n (%) 34 (33.7) 32 (36.8) 0.759
Hospitalization ≥2 days in previous 90 days, n (%) 20 (19.8) 17 (19.5) 1.000
Nursing home resident, n (%) 6 (5.9) 5 (5.7) 1.000
Home infusion therapy, n (%) 2 (2.0) 0 0.500
Home wound care, n (%) 5 (5.0) 3 (3.4) 0.727
Active malignancy, n (%) 8 (7.9) 5 (5.7) 0.774
End-stage liver disease, n (%) 9 (8.9) 1 (1.1) 0.022
COPD, n (%) 15 (14.9) 8 (9.2) 0.271
Steroid use, n (%) 4 (4.0) 7 (8.0) 0.351
Risk factors for MDROs, n (%) 88 (87.1) 70 (80.5) 0.236
Cardiac disease, n (%) 29 (28.7) 25 (28.7) 1.000
Renal disease, n (%) 8 (7.9) 6 (6.9) 1.000
Vascular disease, n (%) 20 (19.8) 27 (31.0) 0.092
End-stage renal disease and/or dialysis, n (%) 4 (4.0) 3 (3.4) 1.000
Diabetes, n (%) 29 (28.7) 17 (19.5) 0.174
Respiratory disease, n (%) 24 (23.8) 18 (20.7) 0.726
Multilobar infiltrates, n (%) 39 (38.6) 25 (28.7) 0.168
Severe sepsis, n (%) 78 (77.2) 55 (63.2) 0.038
Appropriate empiric antimicrobial therapy, n (%) 100 (99.0) 85 (97.7) 0.597
Age, median (IQR) 59 (20) 56 (26) 0.246
Body mass index, median (IQR) 28.7 (11.9) 27.7 (9.9) 0.359
CPIS at diagnosis, median (IQR) 6 (3) 6 (2) 0.177
CPIS at day 3, median (IQR) 7 (3) 7 (3) 0.051
APACHE II score, median (IQR) 21 (11) 19 (9) 0.041
Platelet count at diagnosis, median (IQR) 219 (143) 204 (115.5) 0.397
Hemoglobin at diagnosis, median (IQR) 9.5 (1.9) 10 (2.1) 0.026
Creatinine clearance at diagnosis, median (IQR) 78.5 (59.3) 95.9 (69.3) 0.054
Vancomycin MIC (μg/mL, E-test), n (%) 0.087
0.75 1 (2.4) 0
1 5 (11.9) 0
1.5 22 (52.4) 26 (72.2)
2 14 (33.3) 10 (27.8)
Vancomycin serum trough level (μg/mL),
mean ± SD
Day 3 … 13 ± 8
Overall … 21 ± 11
APACHE, Acute Physiology and Chronic Health Evaluation; COPD, chronic obstructive pulmonary disease; CPIS, Clinical Pulmonary Infection Score; IQR, interquartile
range; MDRO, multidrug-resistant organism; MIC, minimum inhibitory concentration; VAP, ventilator-associated pneumonia.
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Mortality, n (%) 10 (9.9) 8 (9.2) 1.00
Thrombocytopenia, n (%) 18 (17.8) 16 (18.4) 1.00
Anemia, n (%) 43 (42.6) 41 (47.1) 0.559
Nephrotoxicity, n (%) 11 (10.9) 13 (14.9) 0.541
Days on mechanical
ventilation, median (IQR)
11 (14) 13 (11.5) 0.276
Length of stay in
the ICU, median (IQR)
11 (14) 13 (11.5) 0.823
Length of stay in the
hospital, median (IQR)
18 (19) 16 (14.5) 0.773
ICU, intensive care unit; IQR, interquartile range.
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(P = 0.512).
Primary study outcome: clinical success
Unadjusted
The unadjusted clinical success rates for each study arm
were as follows: linezolid, 86/101 (85%); vancomycin, 60/
87 (69%; P = 0.009).
Propensity adjusted
Figure 1 shows the results of the propensity-adjusted re-
gression model for clinical success at day 14. After adjust-
ing for confounding effects, linezolid-treated patients had
statistically significantly higher clinical success rates than
vancomycin-treated patients. These results were consist-
ent across a wide range of APACHE II scores.
Multivariate matching
The results of the final logistic regression model, after
matching, adjustment for the remaining covariate imbal-
ances, and adjustment of the OR to reflect relative risk,
indicated that linezolid-treated patients were 24% more
likely to reach clinical success by day 14 than vancomycin-
treated patients (relative risk, 1.24; 95% confidence inter-
val (CI), 1.06 to 1.32; P = 0.018; adjusted from: OR, 3.53;
95% CI, 1.25 to 9.99; P = 0.018). The adjusted number
needed to treat with linezolid to achieve one extra case of
clinical success compared with vancomycin was six.
Secondary study outcomes
A comparison of unadjusted secondary study outcomes





























Figure 1 Propensity-adjusted logistic regression model for
clinical success at day 14 across a range of Acute Physiology
and Chronic Health Evaluation (APACHE) II scores.Mortality
A total of 18/188 (10%) of patients died. No statistically
significant differences were found between the treatment
groups with respect to mortality.
Safety
Figure 2 depicts Kaplan-Meier survival curves for
anemia, thrombocytopenia, and nephrotoxicity using the
unmatched dataset. No statistically significant differ-
ences were found between the treatment groups with re-
spect to any of the three safety outcomes.
Resource utilization
Figure 3 depicts Kaplan-Meier survival curves for days
on mechanical ventilation, LOS in the ICU, and LOS in
the hospital using the unmatched dataset. No statistically
significant differences were found between the treatment
groups with respect to any of the three resource
utilization outcomes.
Discussion
The results of this study indicate that patients with
MRSA VAP who are treated with linezolid have a signifi-
cantly higher clinical success rate compared with pa-
tients treated with vancomycin. This study did not
identify any significant differences between linezolid-
and vancomycin-treated patients with respect to mortal-
ity, development of thrombocytopenia, anemia, or
nephrotoxicity, mechanical ventilator days, or length of
ICU or hospital stay.
Patients with MRSA VAP who were treated with linez-
olid were approximately 15% more likely to reach clin-
ical success when compared with vancomycin-treated
patients. Six patients with MRSA VAP need to be treated
with linezolid to achieve one additional clinical success.
The difference in clinical success rates between treat-
ment groups in our study is consistent with the 11%
higher clinical success rate for linezolid-treated patients
recently reported in a prospective, double-blind trial [3].
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Figure 2 Kaplan-Meier survival curves for each study arm. (A) Anemia. (B) Thrombocytopenia. (C) Nephrotoxicity.
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linezolid-treated patients in our study is high compared
with success rates reported in previous studies [19-23].
This may be due to our exclusion of patients with a
‘comfort care’ or ‘do not resuscitate’ order and patients
who developed clinical failure during the initial 48 hours
of antibiotic therapy.
There are several reasons why patients treated with
linezolid may have been more likely to reach clinical suc-
cess in our study. First, linezolid-treated patients might
have had less severe disease. Second, vancomycin-treated
patients might have had suboptimal vancomycin trough
levels. Third, the MRSA MIC to vancomycin might have
been in the upper limit within the susceptible range.
Finally, linezolid may be a more effective antibiotic than
vancomycin for the treatment of MRSAVAP.
The possibility that linezolid-treated patients had less
severe disease is an unlikely explanation for our findings.
Linezolid-treated patients had a significantly higher meanDays































































Figure 3 Kaplan-Meier survival curves for each arm. (A) Days on mech
(ICU). (C) LOS of stay in the hospital.APACHE II score and a significantly higher propor-
tion had developed severe sepsis at the time of VAP
diagnosis. This imbalance in the severity of disease
between patients treated with linezolid and vancomycin
was mitigated through the use of a multivariable match-
ing algorithm.
The possibility of suboptimal levels in vancomycin-
treated patients in our study is a consideration. Vanco-
mycin trough levels of 15 to 20 μg/mL may result in better
therapeutic outcomes in patients with VAP than conven-
tional trough levels of 5 to15 μg/mL [2]. In our study, clin-
ical pharmacists were actively involved in the dosing and
management of vancomycin as part of each institution’s
antimicrobial stewardship program. Vancomycin-treated
patients had a mean trough level of 13 ± 8 μg/mL at day
3. We also collected the highest or maximum trough level
at any point during the treatment period. The mean ± SD
of the maximum vancomycin trough level throughout the
treatment duration was 21 ± 11 μg/mL.28
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anical ventilation. (B) Length of stay (LOS) in the intensive care unit
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group reported that mortality among patients with MRSA
HCAP, HAP, and VAP increased as a function of vanco-
mycin MIC [24]. Of the 78 patients in the current study for
whom vancomycin MICs were available, the majority (72
patients) had vancomycin MICs >1 μg/mL. This may ex-
plain the lower success rates seen in the vancomycin group.
Finally, linezolid may be a more effective antibiotic
than vancomycin for the treatment of MRSA VAP. It
also has been hypothesized that the better lung penetra-
tion of linezolid may in part explain the improved out-
comes seen in patients with MRSA VAP [25]. However,
our study cannot address this hypothesis.
The mortality rate in our population was exceedingly
low (10%). However, we identified several reasons that
may explain a low mortality rate in patients with VAP.
First, patients with a ‘comfort care’ or ‘do not resuscitate’
order were excluded from the study. Second, patients
who developed clinical failure during the initial 48 hours
of antibiotic therapy were also excluded. Third, we only
evaluated mortality up to day 14. These three factors
excluded patients with high disease severity and early
mortality as well as patients with late mortality. The low
mortality rate found in this study limits the power to
detect any statistical or clinical differences in mortality be-
tween treatment groups. Moreover, because it has been
suggested that the attributable mortality of VAP is <10%
[26-28], the statistical power to detect differences in
VAP-related mortality is even lower. This low attributable
mortality and the patient’s primary diagnosis requiring
mechanical ventilation make it difficult to ascertain differ-
ences in outcomes beyond clinical success in patients with
VAP. It should be kept in mind that the low mortality ob-
served in our study might be partially due to patients
meeting the CDC criteria for VAP, but in reality having an
alternative diagnosis.
The findings of this study indicate that anemia, throm-
bocytopenia, and nephrotoxicity are frequent events in
ICU patients with MRSA VAP. However, there were no
statistically significant differences in the incidence of these
outcomes in ICU patients with MRSA VAP who were
treated with linezolid or vancomycin. The hematologic
and renal deterioration seen in patients with MRSA VAP
appear independent of antibiotic choice and may be
caused by other conditions common in the critically ill.
We found no difference in resource utilization be-
tween patients with MRSA VAP who were treated with
linezolid versus vancomycin. The large variability of re-
source utilization among ICU patients [29] may explain
why our study failed to detect a difference between treat-
ment groups. To develop interventions to control re-
source utilization and the cost of care among patients
with VAP, factors beyond appropriate antibiotic therapy
should be explored.Our study has several significant limitations. First, this
study was observational in design, which has inherent lim-
itations when compared to randomized clinical trials. Sec-
ond, the VAP diagnosis was based on CDC surveillance
criteria, which may misclassify some cases. The optimal
clinical diagnosis of VAP based on quantitative cultures
obtained from bronchoalveolar lavage was performed in a
limited number of patients. Since most of the micro-
biology was obtained from endotracheal aspirates, we
should emphasize that misclassification of microbio-
logical etiology may have occurred in a significant
number of patients. Third, the follow-up period of the
study was up to 14 days after VAP diagnosis, which
limited our ability to evaluate outcomes occurring at a
later time. The lack of evaluation of mortality at 30 days
weakens our conclusions. Fourth, although clinical phar-
macists were involved in the management of vancomycin
pharmacokinetics, the optimal vancomycin trough level
at day 3 was not achieved in a number of patients. This
observational study represents patients from ICUs in
tertiary care, university-affiliated institutions, which
may limit the generalizability of our study. Finally, we
recognize that we failed to collect information on some
relevant clinical features such as: acute and chronic
tracheostomy, condition and disposition at hospital
discharge, readmission rates, and eradication of MRSA
colonization.
Conclusions
In conclusion, this study adds to the evidence indicating
that patients with MRSA VAP who are treated with li-
nezolid are more likely to respond favorably compared
with patients treated with vancomycin. These results
suggest that linezolid should be considered a preferred
antibiotic for treatment of patients with MRSA VAP.
Key messages
 Patients with MRSA VAP who are treated with
linezolid have a significantly higher clinical success
rate compared with patients treated with
vancomycin.
 Patients with MRSA VAP who were treated with
linezolid were approximately 15% more likely to
reach clinical success when compared with
vancomycin-treated patients.
 This study did not identify any significant
differences between linezolid- and vancomycin-
treated patients with respect to development of
thrombocytopenia, anemia, or nephrotoxicity.
 Resource utilization, measured by days on
mechanical ventilator, or length of ICU or hospital
stay was not different for patients treated with
linezolid or vancomycin.
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